Xagrid
What Xagrid is used for
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Xagrid
- Active substance
- anagrelide
- Disease area
- Thrombocythemia, Essential
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX35
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland
- Authorised in the EU since
- 2004
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xagrid used for?
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events.
What is the active substance in Xagrid?
Xagrid contains anagrelide.
Who makes Xagrid?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU